Back

Parallel disease trajectories of peripheral neurovascular disease and heart failure in type 2 diabetes mellitus: a 12-year prospective follow-up

28 August 2026 (10:15 - 11:00)
Organised by: Logo
Congress Presentation Part of: Diabetes and the heart: pharmacotherapy (1) Pathophysiology ESC2026 Premium Access ESC Congress 2026 European Society of Cardiology

About the speaker

Photo
Doctor Dragica Andric

Institute for Cardiovascular Diseases of Vojvodina, Novi Sad (Serbia)

4 More presentations in this session

Presentation thumbnail
Efficacy of Semaglutide in glycemic control, weight loss, and improving lipid profile- the role of baseline vitamin D levels.
Professor R. Abo Fanne (Hadera, IL)
Abstract Slides
Presentation thumbnail
The association between SGLT2 inhibitors and new-onset osteoporosis in patients with type 2 diabetes: a population-based longitudinal cohort study
Doctor C. Chang (Taichung, TW)
Abstract Slides
Presentation thumbnail
Suboptimal cardioprotective medication prescribing in patients with diabetes and stage B heart failure
Mr M. Hussain (Dundee, GB)
Abstract Slides
Presentation thumbnail
Effects of semaglutide and dapagliflozin on natriuretic peptides in type 2 diabetes: a randomized comparative study
Doctor C. Lejonberg (Helsingborg, SE)
Abstract Slides

Access the full session

Session thumbnail
Diabetes and the heart: pharmacotherapy (1)

The Event

Event poster

ESC Congress 2026

28 August 2026 10:15 CET
You may be interested in
thumbnail
Congress Presentation
Impact of diabetes mellitus on long-term clinical outcomes in patients with moderate diastolic dysfunction and preserved ejection fraction
21 May 2023
thumbnail
Congress Presentation
Hemodynamic arterial changes in heart failure. A proposed new paradigm of heart and vessels failure
29 June 2021
thumbnail
Congress Presentation
Strong association of lower extremity arterial disease and peripheral neuropathy with the development of heart failure in type 2 diabetes
18 May 2025
thumbnail
Congress Presentation
Effect of oral semaglutide on CV outcomes across the vascular disease spectrum, from no vascular disease to polyvascular disease, in high-risk type 2 diabetes
1 September 2025

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources